VACCINE FOR FISH AGAINST HEMORRHAGIC SEPSIS

Patent number:
No items found.

Bacterial hemorrhagic sepsis (formerly known as hemorrhagic septicemia) is a severe systemic disease that affects numerous fish species, particularly under confinement conditions such as in aquaculture facilities, where stress, high stocking density, and skin injuries facilitate infection. The pathogens responsible for sepsis are able to overcome the immune barriers, spread through the bloodstream, and cause internal and external hemorrhages, multi-organ inflammation, and high mortality. This disease can be caused by multiple bacterial species, including Vibrio vulnificus, V. harveyi, Photobacterium damselae subsp. damselae (Pdsd), V. parahaemolyticus, and Aeromonas salmonicida. Among these, V. vulnificus and Pdsd stand out as zoonotic marine pathogens, capable of infecting both fish and humans. In V. vulnificus, the ability to cause sepsis in fish depends, among other factors, on a "fish-blood survival kit" composed of an outer membrane protein and an outer membrane lipoprotein both encoded on transferable plasmids. Only strains that have acquired these genes are capable of causing sepsis in fish. Both genes have also been identified in strains of Pdsd and V. harveyi, among other species. Currently, most commercial vaccines against fish hemorrhagic sepsis are designed to target a single bacterial species and all of them are conventional formulations. The increase in seawater temperature, associated with climate change, is further promoting the proliferation and expansion of V. vulnificus and Pdsd, while also enhancing their virulence, resulting in a greater zoonotic risk for animals and humans. Consequently, it is urgent to develop effective preventive and control strategies against bacterial hemorrhagic sepsis that not only protect against the disease but also limit the transmission of virulence genes among bacteria in aquaculture facilities, thereby contributing to the integrated control of infection and its genetic dissemination within the aquaculture ecosystem, in the framework of a One Health strategy.

Countries:
Spain
Regions:
No items found.
Centers:
UNIVERSITAT DE VALENCIA
Other entities:
Sectors:
Health
Subsectors:
TRL Level:
TRL 4 – technology validated in lab
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
Applications

The main advantages of the developed vaccine are: -Multispecies efficacy, providing cross-protection against different zoonotic pathogens. _Effective preventive application, suitable for both prophylactic programs and outbreak control. _Safe and simple oral administration through feed, enabling large-scale vaccination without the need for direct handling. _High yield and low production cost, suitable for industrial-scale manufacturing. _ No need for additional adjuvants, due to its high intrinsic immunogenicity. _No requirement for biosafety level 2 facilities during production, thereby reducing costs and simplifying manufacturing logistics The main application of this technology is in the field of animal health, specifically in the prevention of bacterial hemorrhagic sepsis in farmed fish. It is especially suitable for use in both marine and freshwater fish farms, where it helps improve animal welfare, reduce losses due to mortality, and promote the sustainability of the aquaculture sector.

Comments

Other related patents

Chemicals
Health

Lumiblast: Mitochondria Sustained Luminescence to Activate a Phototoxin Treating Hard to Reach Tumors

Countries
Spain
Greece
Know more
Health

NANOREP®: NEW TECHNOLOGY FOR THE EASY AND SAFE HANDLING OF OOCYTES AND EMBRYO

Countries
Spain
Know more
Health

DRUG REPOSITIONING FOR THE TREATMENT OF ANEMIAS

Countries
Spain
Know more
Get back to patents directory